Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008–2011
Allison L. Naleway(Centers for Disease Control and Prevention), Eric Weintraub, Claudia Vellozzi(Centers for Disease Control and Prevention), Lisa A. Jackson(Kaiser Permanente Washington Health Research Institute), James G. Donahue(Brigham and Women's Hospital), Nicola P. Klein, Ning Smith(Kaiser Permanente Center for Health Research), Sharon K. Greene(Boston Children's Hospital), Theresa Harrington(Centers for Disease Control and Prevention), Hung Fu Tseng(Kaiser Permanente), Julianne Gee, Brad Crane(Kaiser Permanente), Matthew F. Daley(Kaiser Permanente)
Cited by 21
Related Papers
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|720
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602